Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fenretinide lipid matrix - BioMolecular Products/Lym-Drug Products

Next Previous
X
Search
Drug Profile

Fenretinide lipid matrix - BioMolecular Products/Lym-Drug Products

Alternative Names: 4-HPR/LXS; Fenretinide LYM-X-SORB; HPR/LXS; LXS/4-HPR

Latest Information Update: 02 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomolecular Products; Lym-Drug Products LLC
  • Developer Academic Medical Center; Childrens Hospital Los Angeles; National Cancer Institute (USA)
  • Class Antifibrotics; Antineoplastics; Antivirals; Chemopreventatives; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Insulin resistance
  • No development reported Lymphoma; Neuroblastoma; Solid tumours

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Lymphoma in USA (PO, Controlled release)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Neuroblastoma(Combination therapy, Recurrent) in USA (PO, Controlled release)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Neuroblastoma(Recurrent) in USA (PO, Controlled release)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top